Content
Designed by doctors, shaped by you
Side-by-side medication summaries to compare approved uses, side effects, interactions, and more.
Content
Ozempic
Trulicity
Ozempic® (semaglutide) is an injectable medication used to improve blood sugar control in adults with type 2 diabetes and to reduce the risk of major cardiovascular events in individuals with established heart disease. It works by mimicking the hormone glucagon-like peptide-1 (GLP-1), which increases insulin secretion, decreases glucagon release, and slows gastric emptying. Administered once weekly, Ozempic is often part of a comprehensive treatment plan that includes diet and exercise. Common side effects include nausea, vomiting, diarrhea, and abdominal pain, and it should be used with caution in patients with a history of pancreatitis.
Trulicity® (dulaglutide) is an injectable medication used to improve blood sugar control in adults and pediatric patients aged 10 years and older with type 2 diabetes, alongside diet and exercise. It acts as a glucagon-like peptide-1 (GLP-1) receptor agonist, enhancing insulin secretion, slowing gastric emptying, and reducing glucagon production. Additionally, Trulicity is indicated to reduce the risk of major adverse cardiovascular events, such as heart attack, stroke, and cardiovascular death in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. Administered once weekly, Trulicity can be used alone or with other diabetes medications. Common side effects include gastrointestinal issues like nausea, diarrhea, and vomiting. It should be used cautiously in individuals with a history of pancreatitis.
Prescription
Prescription
Glucagon-like peptide-1 (GLP-1) receptor agonist
Glucagon-like peptide-1 (GLP-1) receptor agonist
Ozempic (semaglutide) is indicated:
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease
Trulicity (dulaglutide) is indicated:
As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors
Typically taken as an injection once weekly
Comes in single-patient-use pens that deliver 0.25 mg, 0.5 mg, 1 mg, or 2 mg per injection
Typically taken as an injection once weekly
Comes in 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg per 0.5 mL single-dose pens
The most common adverse reactions, reported in ≥5% of patients are:
Nausea
Vomiting
Diarrhea
Abdominal pain
Constipation
Most common adverse reactions (incidence ≥5%) are:
Nausea
Diarrhea
Vomiting
Abdominal pain
Decreased appetite
Personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2
Serious hypersensitivity reaction to semaglutide or any of the excipients in Ozempic
Drug interactions: Ozempic delays gastric emptying and may impact the absorption of concomitantly administered oral medications
Patients with a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2
Patients with a serious hypersensitivity reaction to dulaglutide or any of the product components
Drug interactions: Trulicity delays gastric emptying and has the potential to reduce the rate of absorption of concomitantly administered oral medications
Pancreatitis
Diabetic retinopathy complications
Never share an Ozempic pen between patients, even if the needle is changed
Low blood sugar: Concomitant use with an insulin secretagogue or insulin may increase the risk of low blood sugar, including severe low blood sugar
Acute kidney injury
Hypersensitivity reactions
Acute gallbladder disease
Females and males of reproductive potential: Discontinue Ozempic in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide
Thyroid C-cell tumors
Pancreatitis
Low blood sugar: Concomitant use with an insulin secretagogue or insulin may increase the risk of low blood sugar, including severe low blood sugar
Hypersensitivity reactions
Acute kidney injury
Severe gastrointestinal disease
Diabetic retinopathy complications
Acute gallbladder disease
Pregnancy: Should be used during pregnancy only if the potential benefit justifies the potential risk to fetus
WARNING: RISK OF THYROID C-CELL TUMORS
In rodents, semaglutide causes thyroid C-cell tumors. It is unknown whether Ozempic causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
Ozempic is contraindicated in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.
WARNING: RISK OF THYROID C-CELL TUMORS
Dulaglutide causes thyroid C-cell tumors in rats. It is unknown whether Trulicity causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined.
Trulicity is contraindicated in patients with a personal or family history of MTC and in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.
*This information is from the label for brand name Ozempic®. See the Full Prescribing Information for more complete information. Semaglutide, the active ingredient in Ozempic, is also the active ingredient in other brand-name medications, including Rybelsus® and Wegovy®, and this information may not be accurate for all medications that include the active ingredient semaglutide.
*This information is from the label for brand name Trulicity®. See the Full Prescribing Information for more complete information.
The information provided here is NOT MEDICAL ADVICE and is for informational and educational purposes only. The drug comparison tool does not determine eligibility for medications or treatments provided via the Hims/Hers platform. Consultation with a healthcare provider is required to assess suitability for any medical treatment based on individual health and medical history. All product names and associated trademarks are the property of their respective owners.